GenVec/Parke-Davis BioByPass set to enter clinicals in early 1998; companies sign $100 mil. R&D agreement.
Executive Summary
GENVEC/PARKE-DAVIS BIOBYPASS TO BEGIN CLINICALS IN FIRST QUARTER 1998 in the initial indication of coronary artery disease. Patients in the trial will receive a one-time injection to the left ventricle of the gene therapy product, which delivers the vascular endothelial growth factor gene via an adenovirus vector. GenVec licenses the VEGF gene from Scios. A second study in peripheral vascular disease with BioByPass will follow soon after the first study.